Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 70, Issue 8, 2010, Pages 541-546

  Yilmaz, Yusuf ^a   Yonal, Oya ^a   Kurt, Ramazan ^a   Oral, Arzu Y ^b   Eren, Fatih ^c   Ozdogan, Osman ^a   Ari, Ferda ^b   Celikel, Cigdem A ^a   Korkmaz, Seniz ^b   Ulukaya, Engin ^b   Imeryuz, Nese ^a   Kalayci, Cem ^a   Avsar, Erol ^a  

^a MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b ULUDAG UNIVERSITY   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

Author keywords

Enzyme linked immunosorbent assay; Liver biopsy; Nonalcoholic fatty liver disease; Osteoprotegerin

Indexed keywords

OSTEOPROTEGERIN;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ALCOHOLS; CASE-CONTROL STUDIES; DIAGNOSIS, DIFFERENTIAL; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPROTEGERIN; ROC CURVE;

EID: 78649309015     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2010.524933     Document Type: Article

References (30)

1. Erickson SK. Nonalcoholic fatty liver disease. J Lipid Res 2009;50: S412-6.
2. Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci 2005;50:171-80.
3. Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 2009;8: S18-24.
4. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond) 2009;116:539-64.
5. Grønbaek H, Thomsen KL, Rungby J, Schmitz O, Vilstrup H. Role of nonalcoholic fatty liver disease in the development of insulin resistance and diabetes. Expert Rev Gastroenterol Hepatol 2008;2:705-11.
6. Yilmaz Y, Ulukaya E, Gul OO, Arabul M, Gul CB, Atug O, Oral AY, Aker S, Dolar E. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009;42:802-7.
7. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol 2009;88:1-17.
8. Dovio A, Data V, Angeli A. Circulating osteoprotegerin and soluble RANKL: do they have a future in clinical practice? J Endocrinol Invest 2005;28(10 Suppl): 14-22.
9. Zdzisińska B, Bojarska-Junak A, Walter-Croneck A, Kandefer-Szerszeń M. Dysregulation of the receptor activator of NF-kappaB ligand and osteoprotegerin production influence the apoptosis of multiple myeloma patients ' bone marrow stromal cells co-cultured with myeloma cells. Arch Immunol Ther Exp (Warsz) 2010;58:153-63.
10. Chamoux E, Houde N, L'Eriger K, Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol 2008;216:536-42.
11. Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC. Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem 2009;108:106-16.
12. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther 2009;30:1103-9.
13. Feldstein AE, Gores GJ. Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci 2005;10:3093-9.
14. Jou J, Choi SS, Diehl AM. Mechanisms of disease progression in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:370-9.
15. Yilmaz Y, Kedrah AE, Ozdogan O. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol 2009;15:4387-91.
16. Ugur-Altun B, Altun A, Gerenli M, Tugrul A. The relationship between insulin resistance assessed by HOMA-IR and serum osteoprotegerin levels in obesity. Diabetes Res Clin Pract 2005;68:217-22.
17. Ugur-Altun B, Altun A. Circulating leptin and osteoprotegerin levels affect insulin resistance in healthy premenopausal obese women. Arch Med Res 2007;38:891-6.
18. An JJ, Han DH, Kim DM, Kim SH, Rhee Y, Lee EJ, Lim SK. Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med J 2007;48:765-72.
19. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care 2006;29:1955-62.
20. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109:433-8.
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
22. Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Mühllechner P, Habior A, Graziadei I, Vogel W, Tilg H. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol 2005;43:973-83.
23. Fábrega E, Orive A, García-Suarez C, García-Unzueta M, Antonio Amado J, Pons-Romero F. Osteoprotegerin and RANKL in alcoholic liver cirrhosis. Liver Int 2005;25:305-10.
24. García-Valdecasas-Campelo E, González-Reimers E, Santolaria-Fernández F, De La Vega-Prieto MJ, Milena-Abril A, Sánchez-Pérez MJ, Martínez-Riera A, Gómez- Rodríguez Mde L. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease. Alcohol Alcohol 2006;41:261-6.
25. Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, Lakatos P. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol 2003;38:395-400.
26. Yin XM, Ding WX. Death receptor activation-induced hepatocyte apoptosis and liver injury. Curr Mol Med 2003;3:491-508.
27. Emanuele E, Peros E, Scioli GA, D'Angelo A, Olivieri C, Montagna L, Geroldi D. Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer ' s disease. Int J Mol Med 2004;13:849-53.
28. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005;182:175-80.
29. Emanuele E. Is biopsy always necessary? Toward a clinicolaboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. Hepatology 2008;48:2086-7.
30. Yilmaz Y, Ulukaya E, Dolar E. A ' biomarker biopsy ' for the diagnosis of NASH: promises from CK-18 fragments. Obes Surg 2008;18:1507-8.